scholarly journals Short-chain fatty acids, prebiotics, synbiotics, and systemic inflammation: a systematic review and meta-analysis

2017 ◽  
pp. ajcn156265 ◽  
Author(s):  
Rebecca F McLoughlin ◽  
Bronwyn S Berthon ◽  
Megan E Jensen ◽  
Katherine J Baines ◽  
Lisa G Wood
2001 ◽  
Vol 33 ◽  
pp. A68
Author(s):  
A. D'Arienzo ◽  
R. Bennato ◽  
F. Manguso ◽  
G. Vicinanza ◽  
M. Sanges ◽  
...  

2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Mei Luo ◽  
Xiaojun Zhuang ◽  
Zhenyi Tian ◽  
Lishou Xiong

Abstract Background Short-chain fatty acids (SCFAs) and serotonin (5-hydroxytryptamine, 5-HT) may be associated with the pathogenesis of irritable bowel syndrome (IBS). There are some reports of alterations in SCFAs and 5-HT in IBS, but their results are inconsistent. We aimed to perform a meta-analysis to assess alterations in SCFAs and 5-HT in IBS patients and their potential role in the abnormal brain-gut-microbiota (BGM) axis. Methods Case–control studies detecting SCFAs and 5-HT in IBS patients were identified from PubMed, Web of Science, Cochrane Library, and Scopus databases to identify relevant articles up to September 2018. The standardized mean differences (SMDs) with 95% confidence intervals (CIs) of SCFAs and 5-HT were calculated by REVIEW MANAGER 5.3 to evaluate the alterations of 5-HT and SCFAs in IBS. Results Five studies on SCFAs and 5 on 5-HT in IBS patients were included. As compared to healthy controls (HCs), the SMDs of 5-HT in IBS patients was 2.35 (95% CI 0.46–4.24) and the SMDs of total SCFAs, acetic acid, propionic acid, and butyric acid in IBS patients were − 0.01 (95% CI − 0.57–0.55), − 0.04 (95% CI − 0.55–0.47), 0.07 (95% CI − 0.45–0.60), and − 0.00 (95% CI − 0.49–0.49), respectively. Conclusions There was an increase in 5-HT in blood of IBS patients, indicating the increased 5-HT in blood may be involved in IBS pathogenesis. However, there were no significant differences in SCFAs in feces between IBS patients and HCs. But the study did not differentiate between subgroups of IBS. These findings might provide insight for future studies of the BGM axis in the pathogenesis of IBS. Mei Luo and Xiaojun Zhuang contributed equally to the writing of this article


2011 ◽  
Vol 140 (5) ◽  
pp. S-860 ◽  
Author(s):  
Roel J. Vonk ◽  
Marion Priebe ◽  
Kees Meijer ◽  
Koen Venema ◽  
Han Roelofsen

2020 ◽  
Vol 76 (5) ◽  
pp. 297-304
Author(s):  
Nina Kaczmarek ◽  
Marta Kokot ◽  
Aleksandra Makarewicz ◽  
Aleksandra Glapa-Nowak ◽  
Jan Nowak ◽  
...  

Nutrients ◽  
2019 ◽  
Vol 11 (10) ◽  
pp. 2512 ◽  
Author(s):  
Kyu Nam Kim ◽  
Yao Yao ◽  
Sang Yhun Ju

There have been mixed results regarding the relationship among short chain fatty acids (SCFAs), microbiota, and obesity in human studies. We selected studies that provided data on SCFA levels or fecal microbiota abundance in obese and nonobese individuals and then combined the published estimates using a random-effects meta-analysis. Obese individuals had significantly higher fecal concentrations of acetate (SMD (standardized mean differences) = 0.87, 95% CI (confidence interva) = 0.24–1.50, I2 (I–squared) = 88.5), propionate (SMD = 0.86, 95% CI = 0.35–1.36, I2 = 82.3%), and butyrate (SMD = 0.78, 95% CI = 0.29–1.27, I2 = 81.7%) than nonobese controls. The subgroup analyses showed no evidence of heterogeneity among obese individuals with a BMI >30 kg/m2 (I2 = 0.0%). At the phylum level, the abundance of fecal microbiota was reduced in obese compared to nonobese individuals, but the difference was not statistically significant (Bacteroidetes phylum, SMD = −0.36, 95% CI = −0.73–0.01; Firmicutes phylum, SMD = −0.10, 95% CI = −0.31–0.10). The currently available human case-control studies show that obesity is associated with high levels of SCFA but not gut microbiota richness at the phylum level. Additional well-designed studies with a considerable sample size are needed to clarify whether this association is causal, but it is also necessary to identify additional contributors to SCFA production, absorption, and excretion in humans.


1994 ◽  
Vol 92 (4) ◽  
pp. 629-635 ◽  
Author(s):  
Mercedes Gallardo ◽  
Paloma Munoz De Rueda ◽  
Angel Jesus Matilla ◽  
Isabel Maria Sanchez-Calle

Diabetes ◽  
2018 ◽  
Vol 67 (Supplement 1) ◽  
pp. 92-OR ◽  
Author(s):  
WEI HUANG ◽  
YONG XU ◽  
YOUHUA XU ◽  
LUPING ZHOU ◽  
CHENLIN GAO

Diabetes ◽  
2020 ◽  
Vol 69 (Supplement 1) ◽  
pp. 1898-P
Author(s):  
ADELINA I.L. LANE ◽  
SAVANNA N. WENINGER ◽  
FRANK DUCA

Sign in / Sign up

Export Citation Format

Share Document